Marc said eftilagimod doubles indications for Keytruda. But what he didn’t say was that combining eftilagimod with any competing PD1 drug will greatly increase competition for Keytruda.
Something Merck probably knows
Overnight Market report, page-1483
-
- There are more pages in this discussion • 1,360 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.8¢ |
Change
-0.003(0.63%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.5¢ | $1.158M | 2.894M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 205390 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 174398 | 17 |
View Market Depth
| Last trade - 15.40pm 11/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |